| Literature DB >> 31807242 |
Amna Shahid1, Syeda Durr-E-Shahwar Zaidi1, Haroon Akbar2, Sania Saeed1.
Abstract
OBJECTIVES: Pyriproxyfen as an insect growth regulator is widely used globally for pest management. There are reports on adverse effects of insecticides such as organ toxicity, endocrine disruptions, and teratogenicity in animals and humans. We aimed to investigate reproductive toxicity of pyriproxyfen in adult male mice.Entities:
Keywords: Endocrine disruptor; Histopathology; Leydig cells; Pyriproxyfen; Reproductive toxicity; Seminiferous tubules
Year: 2019 PMID: 31807242 PMCID: PMC6880530 DOI: 10.22038/ijbms.2019.33825.8051
Source DB: PubMed Journal: Iran J Basic Med Sci ISSN: 2008-3866 Impact factor: 2.699
Body, testis, and relative testis weights of different groups
| Initial | Final body weights | Right testis weights | Relative right testis weights | Left testis weights | Relative left testis weights | |
|---|---|---|---|---|---|---|
| Control | 23.13 ± 0.49 | 32.51 ± 1.46 | 0.085 ± 0.44 | 0.261 ± 0.02 | 0.084 ± 0.41 | 0.258 ± 0.02 |
| 1200 mg/kg | 19.85 ± 0.91*** | 20.90 ± 0.57*** | 0.064 ± 0.40* | 0.306 ± 0.01 | 0.064 ± 0.57* | 0.306 ± 0.01 |
| 600 mg/kg | 21.2 ± 0.70*** | 20.58 ± 1.04*** | 0.069 ± 0.56* | 0.335 ± 0.01 | 0.069 ± 0.45* | 0.335 ± 0.01 |
| 320 mg/kg | 20.21 ± 1.14*** | 21.61 ± 1.02*** | 0.074 ± 0.41 | 0.342 ± 0.02 | 0.074 ± 0.27 | 0.342 ± 0.001 |
| 200 mg/kg | 21.85 ± 0.95*** | 22.85 ± 1.30*** | 0.076 ± 0.38 | 0.332 ± 0.002 | 0.074 ± 0.37 | 0.323 ± 0.009 |
| 100 mg/kg | 21.63 ± 0.30*** | 22.16 ± 0.76*** | 0.078 ± 0.32* | 0.351 ± 0.007 | 0.082 ± 0.41 | 0.370 ± 0.002 |
| 40 mg/kg | 22.56 ± 0.26 | 23.11 ± 0.45*** | 0.083 ± 0.26 | 0.359 ± 0.001 | 0.087 ± 0.37 | 0.376 ± 0.001 |
| 20 mg/kg | 23.18 ± 0.41* | 24.40 ± 0.40*** | 0.083 ± 0.28 | 0.340 ± 0.009# | 0.085 ± 0.55 | 0.348 ± 0.006# |
Values are expressed as mean ± SEM (n=6). One-way ANOVA followed by Tukey’s test, *** P<0.001, * P<0.05 and # (not significant) represents comparison to control and treated groups
Figure 1Mean body weights of mice in control and pyriproxyfen treated groups during 28 consecutive days
Determination of structural changes by histopathological examination of the albino mice testis in the different treatment groups
| Groups | Doses | Spermatids | Spermatozoa | Leydig cells | Sperm density | Degenerative changes in tunica albuginea | Intratubular space |
|---|---|---|---|---|---|---|---|
| Control |
|
|
|
|
|
| |
| I | 1200 |
|
|
|
|
|
|
| II | 600 |
|
|
|
|
|
|
| III | 320 |
|
|
|
|
|
|
| IV | 200 |
|
|
|
|
|
|
| V | 100 |
|
|
|
|
|
|
| VI | 40 |
|
|
|
|
|
|
| VII | 20 |
|
|
|
|
|
|
++++ indicates extremely severe, +++ indicates severe, ++ indicates moderate, + indicates mild, - indicates absent
Figure 4(A) Control group mice testes after 28 days of experimental period showing normal testicular tissue with mature spermatozoa (MSP), normal seminiferous tubules (SFT) with normal basement membrane tunica albuginea (TA), reduced lumen (L), increased number of Leydig cells (Lc) and primary spermatozoa (Ps) and secondary spermatozoa (Ss) were also present. (B) Pyriproxyfen treated group (1200 mg/kg) showing reduced lumen (L), more intra seminiferous tubular space (IST), more clumping of spermatozoa (CSP), degenerative changes in tunica albuginea (DGTA), more degenerative spermatozoa (DSP), and Leydig cells (Lc) were absent. Figure (C) Pyriproxyfen treated group (600 mg/kg) showing reduced lumen (L), less intra seminiferous tubular space (IST), degenerative changes in tunica albuginea (DTA), clumped spermatozoa (CSP), vacuolization (V), and degenerative Leydig cells (Lc) were present. Figure (D) Pyriproxyfen treated group (320 mg/kg) showing less, seminiferous tubular space (IST), moderate degenerative changes in tunica albuginea (MDCTA), lower number of Leydig cells (Lc), more vacuolization (V). Figure (E) Pyriproxyfen treated group (200 mg/kg) showing mild degenerative changes in tunica albuginea (MDCTA), presence of Leydig cells (Lc), less clumping of spermatozoa (CSP) and increase in the lumen (L). Figure (F) Pyriproxyfen treated group (100 mg/kg) showing lumen (L), primary spermatozoa (Ps), less degenerative changes in the tunica albuginea (LDCTA), and Leydig cells (Lc) were present. Figure (G) Pyriproxyfen treated group (40 mg/kg) showing higher number of sperms (S), and Leydig cells (Lc) with normal tunica albuginea (TA). Figure (H) Pyriproxyfen treated group (20 mg/kg) showing primary spermatozoa (PS), secondary spermatozoa (Ss), increased number of sperms (S), and increased number of Leydig cells (Lc)
Figure 2Mean diameter of seminiferous tubules (1 µm2) in the testis of mice in control and pyriproxyfen treated groups. *: a significant difference between control and 1200 mg/kg groups (P<0.05). **: a significant difference between control and treated (600 mg/kg) groups (P<0.01)
Figure 3Mean Leydig cell count (1 µm2) in the testis of mice in control and pyriproxyfen treated groups. ***: a significant difference between control and 1200 mg/kg groups (P<0.001). **: a significant difference between control and treated (600 mg/kg and 320 mg/kg) groups (P<0.01)
Mean diameter of seminiferous tubules (1 µm2) in testes in different groups
| Groups | Doses (mg/kg) | Mean diameter of seminiferous tubules (1 µm2) X ± SEM |
|---|---|---|
| Control | 0 | 217.86 ± 4.14 |
| I | 1200 | 191.10 ±5.94* |
| II | 600 | 185.68 ± 4.52** |
| III | 320 | 198.11 ± 5.94 |
| IV | 200 | 207.43 ± 4.43 |
| V | 100 | 205.80± 6.29 |
| VI | 40 | 203.33 ± 7.43 |
| VII | 20 | 210.33 ± 5.24 |
* P<0.05 and **P<0.01 indicate significant difference between treated mice groups (1200 and 600 mg/kg) and control group.
Mean distribution of Leydig cells (1 µm2) in different groups
| Groups | Doses (mg/kg) | Mean |
|---|---|---|
| Control | 0 | 17.01 ± 1.08 |
| I | 1200 | 4.25 ± 0.85*** |
| II | 600 | 8.25 ± 0.94** |
| III | 320 | 9.50 ± 1.04** |
| IV | 200 | 12.50 ± 0.85 |
| V | 100 | 14.31 ± 1.87 |
| VI | 40 | 15.75 ± 2.21 |
| VII | 20 | 16.23 ± 0.70 |
** P<0.01 indicates significant difference between control and treated groups (600 and 320 mg/kg). *** P<0.001 shows significant difference between the treated group (1200 mg/kg) in comparison with controls.